Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects (Q34307589)

1 August 2017

0 references

Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects (English)

1 reference

1 August 2017

1 reference

S C Sim

1

1 reference

1 August 2017

M Kacevska

series ordinal

2

1 reference

1 August 2017

M Ingelman-Sundberg

series ordinal

3

1 reference

1 August 2017

publication date

23 October 2012

1 reference

The Pharmacogenomics Journal

1 August 2017

published in

1 reference

1 August 2017

volume

13

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

1-11

1 reference

Pharmacogenomic biomarkers: new tools in current and future drug therapy

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Gilbert syndrome redefined: a complex genetic haplotype influences the regulation of glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A genome-wide linkage study of individuals with high scores on NEO personality traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genome-wide association study identifies eight loci associated with blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genome-wide meta-analyses identify multiple loci associated with smoking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genome-wide association study of smoking behaviours in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A genome-wide association study of acenocoumarol maintenance dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Clopidogrel: a case for indication-specific pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Pharmacogenetics of antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 and the severity of suicide attempts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2C19 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

CYP2D6 in the brain: genotype effects on resting brain perfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Genome-wide association meta-analysis for total serum bilirubin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

UGT1A1 is a major locus influencing bilirubin levels in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2012.45

21 January 2018

Identifiers

DOI

10.1038/TPJ.2012.45

1 reference

Dimensions Publication ID

1 August 2017

1048934339

0 references

1 reference